Showing results (351-360 of 404) with videos related to
Sort By:
Pageof 41
World Journal of Clinical Oncology|December 15, 2021
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case seriesSebastiano Buti, Melissa Bersanelli, Francesco Massari, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 30, 2022
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trialGerardo Rosati, Chiara Alessandra Cella, Luigi Cavanna, et al.Plos One|May 26, 2016
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC StudyStefania Gori, Alessandro Inno, Valentina Rossi, et al.Scientific Reports|January 23, 2023
Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, et al.Cancers|September 23, 2022
Thrombin Generation and D-Dimer for Prediction of Disease Progression and Mortality in Patients with Metastatic Gastrointestinal CancerCinzia Giaccherini, Cristina Verzeroli, Laura Russo, et al.NPJ Breast Cancer|July 20, 2022
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancerElisa Agostinetto, Lieveke Ameye, Samuel Martel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2018
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant TrialAlberto Sobrero, Sara Lonardi, Gerardo Rosati, et al.TH Open : Companion Journal to Thrombosis and Haemostasis|February 15, 2021
Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease RecurrencePatricia Gomez-Rosas, Marina Pesenti, Cristina Verzeroli, et al.The Oncologist|June 8, 2021
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority StudyLuigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, et al.BMC Cancer|August 23, 2022
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 studyLuigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, et al.Pageof 41